Literature DB >> 11739982

Effect and feasibility of controlled rewarming after moderate hypothermia in stroke patients with malignant infarction of the middle cerebral artery.

T Steiner1, T Friede, A Aschoff, P D Schellinger, S Schwab, W Hacke.   

Abstract

BACKGROUND AND
PURPOSE: Moderate hypothermia has been found to reduce intracranial pressure (ICP) significantly in patients who have severe middle cerebral artery infarction. However, during passive rewarming, ICP continuously rises and some patients suffer transtentorial herniation.
METHODS: We investigated the question of whether slower rewarming leads to slower increase in ICP and slower decrease in cerebral perfusion pressure (CPP). Furthermore, we studied feasibility of slow, controlled rewarming. ICP, CPP, and core body temperature were monitored continuously. Achievement of rewarming protocol was assessed by hit rate of temperature target intervals. Side effects of hypothermia were assessed.
RESULTS: Rates of change of both ICP and CPP were correlated significantly with increase in temperature (ICP r=0.62, P=0.002; CPP r=-0.50, P=0.017). In feasibility analysis of 13 controlled rewarmed patients, hit rate of temperature target intervals was 63% (median; range 48% to 81%); hit rate within the target interval or below was 79% (median; range 62% to 94%).
CONCLUSIONS: Slow, controlled rewarming is feasible and may be used for ICP and CPP control after moderate hypothermia for space-occupying infarction.

Entities:  

Mesh:

Year:  2001        PMID: 11739982     DOI: 10.1161/hs1201.99511

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  26 in total

Review 1.  The search for neuroprotective strategies in stroke.

Authors:  Gary H Danton; W Dalton Dietrich
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

2.  Delayed hypothermia in malignant ischaemic stroke.

Authors:  Vincenzo Di Lazzaro; Paolo Profice; Michele Dileone; Giacomo Della Marca; Cesare Colosimo; Emanuele Pravatà; Antonino Pavone; Mariano Pennisi; Riccardo Maviglia; Fabio Pilato
Journal:  Neurol Sci       Date:  2011-10-15       Impact factor: 3.307

Review 3.  Decompressive craniectomy as a therapeutic option in the treatment of hemispheric stroke.

Authors:  Justin F Fraser; Roger Hartl
Journal:  Curr Atheroscler Rep       Date:  2005-07       Impact factor: 5.113

Review 4.  Neuroprotection for ischemic stroke using hypothermia.

Authors:  Angelos-Aristeidis Konstas; Jae H Choi; John Pile-Spellman
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 5.  Hemicraniectomy for middle cerebral artery infarction.

Authors:  Hagen B Huttner; Eric Jüttler; Stefan Schwab
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

Review 6.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

7.  Evidence-based guidelines for the management of large hemispheric infarction : a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-intensive Care and Emergency Medicine.

Authors:  Michel T Torbey; Julian Bösel; Denise H Rhoney; Fred Rincon; Dimitre Staykov; Arun P Amar; Panayiotis N Varelas; Eric Jüttler; DaiWai Olson; Hagen B Huttner; Klaus Zweckberger; Kevin N Sheth; Christian Dohmen; Ansgar M Brambrink; Stephan A Mayer; Osama O Zaidat; Werner Hacke; Stefan Schwab
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

Review 8.  [News and perspectives in neurocritical care].

Authors:  J Bösel; M Möhlenbruch; O W Sakowitz
Journal:  Nervenarzt       Date:  2014-08       Impact factor: 1.214

Review 9.  Treatment or prevention of complications of acute ischemic stroke.

Authors:  L J Kappelle; H B Van Der Worp
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

10.  Early changes in physiological variables after stroke.

Authors:  Andrew A Wong; Stephen J Read
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.